EE506 Clinical Consequences and Associated Costs of Treating Patients With Waldenström Macroglobulinemia in the First-Line Setting With Bruton Tyrosine Kinase Inhibitors
Abstract
Authors
S Crawford H Li M Salkar X Yu P Martin
S Crawford H Li M Salkar X Yu P Martin
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now